FindMyKOL
Clinical trialNCT02361840UnknownObservational

Predictive Value of Troponin I for Acute Respiratory Distress Syndrome in Children With Shock

NCT02361840 is an observational study sponsored by Hospital Civil de Guadalajara. As of 21 Nov 2026, it has a status the registry marks as unknown. It studies ARDS. The registry lists an enrollment of 65 participants at 1 site in 1 country. The registry lists a start date of 31 Oct 2012 and a primary completion date of 28 Feb 2015.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02361840
FieldValue
Registry IDNCT02361840
StatusUnknown
Study typeObservational study
Lead sponsorHospital Civil de Guadalajara
Enrollment65
Registered sites1
Countries1
ConditionsARDS
Start31 Oct 2012
Primary completion28 Feb 2015
Study completion28 Feb 2015
Last update posted12 Feb 2015

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Shock is one of the five leading causes of income and mortality in emergencies. It generates a decrease in the availability of oxygen to the tissues, resulting in ischemia, pulmonary involvement and tissue reperfusion syndrome. This pathologies can trigger Syndrome of Acute Respiratory Distress (ARDS) and death. Troponin I (TI) has been reported as early marker for ischemia and mortality other than coronary syndromes in critical patients. Objective. Set the increase of TI as a predictor of ARDS in children with shock. Null hypothesis. Increase serum in children with shock predicts the onset of ARDS. Methodology. Prospective cohort type test diagnostic. Displays institutional. Sampling non-probability, consecutive inclusion. Calculation of the sample size: interval of confidence (IC) 95%, power - 80%; ratio non-exposed: exposed 2:1; n = 62. Inclusion criteria: informed consent signed by the parent; children admitted to pediatric emergency (PEU) 1 month to 14 years with shock requiring mechanical ventilation. Exclusion criteria: intake of toxic (TI value increment per will), ≥3 concentrated erythrocyte transfusion or plasma prior to entering PEU. The investigators call exposure to the increase of TI≥0 05ng/ml and event to the development of ARDS. Determine TI value in plasma serum in the first 24 h, through Enzyme Immunoassay for the Quantitative Determination of Cardiac-Specific Troponin-I in Human Serum (cTnI ELISA), (reported as cardiac triage). Monitoring for 7 days. Study was approved by Hospital Ethics Committee (Research record 003/12)

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Mexico1 site, 1 recruiting
  • Karla Isis Aviles Martinez

    Guadalajara, Jalisco

    Recruiting

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT02361840

Each answer restates registry values shown on this page.

What is NCT02361840?

NCT02361840 is an observational study sponsored by Hospital Civil de Guadalajara. It studies ARDS.

Who leads NCT02361840?

The registry names IRAM ALBERTO VILLA MANZANO, PhD., MD (study director, University of Guadalajara), KARLA ISIS AVILES MARTINEZ, MD (principal investigator, University of Guadalajara) and MONICA CECILIA URIBE MERCADO, PhD., MD (study director, Universidad de Gudadalajara) as overall officials.

Where does NCT02361840 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: Mexico.

When is NCT02361840 expected to complete?

The registry lists a primary completion date of 28 Feb 2015 and a study completion date of 28 Feb 2015. The sponsor last updated the record on 12 Feb 2015.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.